The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased cleavage of BID protein]
pepstatin affects the reaction [thallium nitrate results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pepstatin inhibits the reaction [thallium nitrate analog results in increased activity of CASP3 protein] [aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]
pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] pepstatin inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein modified form]; pepstatin inhibits the reaction [syringic acid analog results in increased secretion of CASP9 protein]
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSB protein
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSD protein; [CA 074 methyl ester co-treated with pepstatin] results in decreased expression of CTSD protein; pepstatin inhibits the reaction [Glucosamine results in decreased expression of CTSD protein alternative form] pepstatin results in decreased activity of CTSD protein
[aloxistatin co-treated with pepstatin] results in increased expression of LAMP2 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of LAMP2 protein
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; pepstatin promotes the reaction [BO-1051 results in increased expression of MAP1LC3B protein modified form] [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [CA 074 methyl ester co-treated with pepstatin] results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein
browse the term
